Understanding long-term psoriasis remission after short-term treatment
A clinical trial for psoriasis with novel single-cell genomic techniques to understand regulatory immunity behind long-term disease remission off drug induced by short-term IL-23 inhibition
['FUNDING_OTHER'] · UNIVERSITY OF CALIFORNIA AT DAVIS · NIH-11145619
This research aims to discover why some people with psoriasis stay clear of symptoms for a long time after a short course of medication, hoping to find ways to achieve lasting relief for more patients.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CALIFORNIA AT DAVIS (nih funded) |
| Locations | 1 site (DAVIS, UNITED STATES) |
| Trial ID | NIH-11145619 on ClinicalTrials.gov |
What this research studies
Many effective psoriasis medications require continuous use to prevent symptoms from returning. This project is looking into why some patients experience long-lasting relief even after stopping a short-term IL-23 blocking treatment. Researchers will examine skin samples from these patients to understand the immune system changes that lead to sustained remission. The goal is to identify specific immune signals before treatment that can predict who might achieve long-term remission, helping doctors personalize care.
Who could benefit from this research
Good fit: Ideal candidates would be individuals with psoriasis who are undergoing or have recently undergone short-term IL-23 blocking antibody treatment.
Not a fit: Patients whose psoriasis does not respond to IL-23 blocking treatments or who are not seeking long-term remission off medication may not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to new strategies for curing psoriasis without recurrence, reducing the need for continuous medication.
How similar studies have performed: While IL-23 inhibitors are known to be effective for psoriasis, this specific approach of using single-cell genomics to understand long-term remission off drug and develop predictive models is a novel area of investigation.
Where this research is happening
DAVIS, UNITED STATES
- UNIVERSITY OF CALIFORNIA AT DAVIS — DAVIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KIM, JAEHWAN — UNIVERSITY OF CALIFORNIA AT DAVIS
- Study coordinator: KIM, JAEHWAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.